after enrollment, you attend a baseline visit where clinical measurements and laboratory tests are performed to document your health status before starting the trial.

the visit also includes collection of information required for later comparison with future assessments.

based on the study design, you are randomly assigned to receive either tirzepatide, retatrutide, or a matching placebo.

randomization ensures that the assignment is unbiased and that the groups are comparable.

on the same day as randomization you receive the first dose of the assigned study medication.

tirzepatide is supplied as a solution for injection in a pre‑filled pen for subcutaneous injection (injection under the skin).

retatrutide is supplied as a solution for injection for subcutaneous injection.

the placebo is provided in a matching injection form.

the exact dose is defined by the trial protocol and is administered according to the instructions given by the study staff.

you continue to self‑administer the study medication by subcutaneous injection at the frequency specified by the protocol.

the schedule is maintained for the entire study period, which may last up to approximately 224 weeks from the baseline visit.

each injection is performed using the device supplied for the assigned product.

throughout the trial you attend scheduled follow‑up visits at the study centre.

during each visit clinical evaluations, safety assessments, and laboratory tests are performed to monitor your response to the medication and to detect any adverse effects.

the timing of these visits follows the schedule defined in the study protocol.

the study monitors the time to the first occurrence of any component of the composite endpoint for major adverse liver outcomes.

these outcomes include progression to cirrhosis, development of large esophageal or gastric varices, ascites, hepatic encephalopathy, variceal hemorrhage, increase in MELD score from ≤12 to ≥15, liver transplantation, and all‑cause mortality.

assessment of these events occurs continuously from baseline until study completion.

the trial concludes after the last scheduled visit, which is expected around week 224 after the baseline visit.

final assessments are performed, and the study data are collected for analysis.